Kaps

KAPS Biotech is a private U.S. biotechnology diagnostics company focused on developing blood-based cancer biomarkers, with its lead effort aimed at improving prostate cancer detection and risk assessment. The company is advancing a multi-analyte biomarker panel that combines immune-related serum markers to improve specificity versus prostate-specific antigen testing alone and to help distinguish aggressive from less aggressive disease. Its scientific foundation was developed by researchers Kailash Chadha and Willie Underwood, and the company has received U.S. government SBIR/STTR support for this work. Based on currently available public information, KAPS Biotech appears to be an early-stage, platform-oriented diagnostics company rather than a therapeutics developer.